DD - LEXX - A biotech company with a patented drug delivery system that can be used both commercially and pharmaceutically
Feel free to remove since it is above the $5 requirement; it is a microcap stock ~35M marketcap, so it also doesn't fit in other subreddits :(
$LEXX (NASDAQ)
| Statistics | Value |
|---|---|
| Outstanding shares | 5.7M |
| Insider Ownership | ~15% (data widely varies) |
| Institutional Ownership | 800K (15%) |
| Float | 3.1M - 4.1M (data widely varies based on insider ownership) |
| Market cap | 36M |
| Current Price | $6.30 |
| 52 week high | $12.50 (squeeze back in July) |
| 52 week low | $3.97 |
| SI % | ~7% |
This is a recent presentation of their current financial status and pipeline..
| Title | Detail |
|---|---|
| Main product: | DehydraTECH |
| Purpose | Drug delivery system - increases absorption by 5 - 10x, and reduces time of onset from hours to minutes |
| Main drug target | Cannabinoids / Nicotine |
| Uses | Cannabinoid / nicotine drinks, clinical drug delivery (CBD / antivirals / antiinflammatories). |
| Commercial Royalty | 3 - 10% |
| Out-Licensing | Altria (non-exclusive agreement; no revenue until nicotine delivery studies are completed), Nic's Berverages (5 year agreement for CBD-based beverages), Universal Hemp (5 year agreement hemp-derived products), Hill Street Beverage Company (10 year agreement for CBD hemp powder) |
Clinical pipeline (6 total studies in pipeline) and results so far (amazing July PR):
-
July 2021 - Dehydratech in vitro assay study with Remdesivir and Ebastine showed inhibition of COVID-19 SARS-CoV-2 virus.
-
July 2021 - Dehydratech rodent study showed significant benefits in Colchicine drug delivery compared to controls. Colchicine is a drug used for the treatment of gout and cardiac inflammation. Current bioavailability in oral delivery is about 45%, with Dehydratech their rodent models showed about 90%.
-
July 2021 - Completed phase 1 trial for the treatment of hypertension with CBD (with Dehydratech delivery). BP was reduced across both male and female volunteers and was most pronounced with DehydraTECH-CBD in the first 10-50 minutes of the study, reinforcing pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic CBD controls.
We should be receiving more data in the coming weeks. I would recommend reading their presentation for more specifics. Below is not all of it, just the main points.
-
August 2021 (still expecting results) - blood chemistry from COVID study
-
September 2021 - blood sample and data analysis of CBD blood pressure study
-
October 2021 - Animal tolerability results for nicotine study
-
November 2021 - NSAID animal tolerability test results.
Financials
2019 Revenue - 222k (EPS -0.05)
2020 Revenue - 384k (EPS -0.04)
9M-2021 - 691k (EPS -0.71)
2021E- 916k
2022E - 1.7M
2019 Cash - 1.3M
2020 Cash - 1.3M
9M-2021 Cash - 8.1M
2019 Debt - Nil
2020 Debt - 30k
9M-2021 Debt - 7.5k
Fair Value Estimate - $10.51
According to the CEO in the last meeting, he mentioned that they have received communication for potential buyouts. He has routinely turned them down, unless they are willing to offer a fair valuation of 300M minimum.
Based on competitors, the CEO also expects the valuation to continue upwards and is running for XXXM - 1B valuation in the coming years.
Posted Sep 4, 2021, 3:02 PM UTC · edited
Does this submission fit our subreddit? If it does please upvote this comment. If it does not fit the subreddit please downvote this comment.
^(I am a bot, and this comment was made automatically.) ^(Please) ^(contact)^( )^(us)^( )^(via)^( )^(modmail) ^(if) ^(you) ^(have) ^(any) ^(questions) ^(or) ^(concerns.)